Please select the option that best describes you:
Topics:
Breast Cancer • Radiation Oncology
Which patient subgroups do you plan to omit regional nodal irradiation for, given the publication of NSABP B-51?
Do you feel that 5 years of follow-up is adequate to change management?
If you will defer, how will your approach differ for triple-negative vs. ER/PR-negative, but HER2-positive patients?
Answer from: Radiation Oncologist at Academic Institution
I will await more data with subgroup analysis prior to changing my practice pattern.
Sign in or Register to read more